返回
Celcuity Inc（CELC）价格
CELC 股价走势图
CELC 收益
Celcuity Inc
$105.39
-1.46%
$-1.56
收盘价：Jan 20, 16:00:00 GMT-5
$106.5
1.05%
$1.1
盘后：Jan 20, 20:00:00 GMT-5
关键数据
前收盘价
$106.96
开盘价
$104
当日区间
$103 - $108.03
52周范围
$7.57 - $116.44
交易量
720.0K
平均成交量
988.8K
每股收益（TTM）
-3.67
股息收益率
--
市值
$4.9B
什么是 CELC？
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.